GE to distribute Gamma Medica-Ideas pre-clinical imaging products
Gamma Medica-Ideas (GM-I) and GE Healthcare announced a partnership at the 55th annual meeting of the Society of Nuclear Medicine (SNM) in New Orleans, for which GE will be the exclusive distributor of GM-I's pre-clinical imaging products starting July 1.
Pre-clinical imaging plays a key role in new pharmaceutical therapeutic development by allowing researchers to visualize the structure, function and response of laboratory animals in vivo, according to GE.
GE said the agreement complements its portfolio of pre-clinical products, and grants researchers greater access to GM-I’s innovative, fully digital tri-modality PET, SPECT and CT scanners.
“Researchers across the globe will reap the benefits of the combined multi-modality pre-clinical portfolio of GE Healthcare and Gamma Medica-Ideas accelerating studies to investigate disease biology and develop new drugs,” said James Mitchell, general manager, molecular imaging technologies, GE Healthcare. “This agreement makes for a one-stop-shop for pre-clinical imaging devices.”
Pre-clinical imaging plays a key role in new pharmaceutical therapeutic development by allowing researchers to visualize the structure, function and response of laboratory animals in vivo, according to GE.
GE said the agreement complements its portfolio of pre-clinical products, and grants researchers greater access to GM-I’s innovative, fully digital tri-modality PET, SPECT and CT scanners.
“Researchers across the globe will reap the benefits of the combined multi-modality pre-clinical portfolio of GE Healthcare and Gamma Medica-Ideas accelerating studies to investigate disease biology and develop new drugs,” said James Mitchell, general manager, molecular imaging technologies, GE Healthcare. “This agreement makes for a one-stop-shop for pre-clinical imaging devices.”